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OBJECTIVE
It is predicted that Africa will have the greatest increase in the number of patients
with type 2 diabetesmellitus (T2DM)within the next decade. T2DMpatients are at
risk for cardiovascular disorders. In Sub-Saharan African countries, sickle cell trait
(SCT) is frequent. Despite the presence of modest abnormalities in hemorheology
and oxidative stress, SCT is generally considered a benign condition. Little is
known about vascular function in SCT, although recent studies demonstrated an
increased risk of cardiovascular disorders, including venous thromboembolism,
stroke, and chronic kidney disease. We hypothesized that SCT could accentuate
the vascular dysfunction observed in T2DM.
RESEARCH DESIGN AND METHODS
The current study, conducted in Senegal, compared vascular function, hemorheological
profile, and biomarkers of oxidative stress, inflammation, and nitric oxidemetabolism
inhealthy individuals (CONT), subjectswith T2DMor SCT, andpatientswith both T2DM
and SCT (T2DM-SCT).
RESULTS
Flow-mediated dilationwas blunted in individuals with T2DM, SCT, and T2DM-SCT
compared with CONT, with vascular dysfunction being most pronounced in the
latter group. Carotid-femoral pulse wave velocity measurements demonstrated
increased arterial stiffness in T2DM-SCT. Oxidative stress, advanced glycation end
products, and inflammation (interleukin-1b)were greater in patientswith T2DM-SCT
compared with the other groups. Blood viscosity was higher in individuals with
TD2M, SCT carriers, and individuals with T2DM-SCT, and the values were further
increased in the latter group.
CONCLUSIONS
Our results demonstrate severe biological abnormalities and marked vascular
dysfunction in patients with both T2DM and SCT. SCT should be viewed as a risk
factor for further cardiovascular disorders in individuals with T2DM.
Chronic hyperglycemia, hyperlipidemia, and hyperinsulinemia cause endothelial
and vascular dysfunction in large arteries and microcirculation of patients with
type 2 diabetes mellitus (T2DM) (1). Elevated glycemia accelerates the formation
of advanced glycation end products (AGEs), which generate reactive oxygen species
(ROS) and promote inflammation (2). Impaired endothelial nitric oxide (NO)
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synthase activity due to progressive insulin
resistance and reduced NO bioavailability
caused by enhanced oxidative stress result
in impaired vascular reactivity (1). T2DM
is a major public health problem world-
wide, and recent epidemiological data
predict that Africa, and more particularly
Sub-Saharan countries,will have the great-
est increase in the number of people with
T2DM, from 19.8 million in 2013 to 41.4
million in2035, if current trendspersist (3).
Concomitantly, in Sub-Saharan African
countries, sickle cell trait (SCT) is highly
prevalent (4). SCT is the heterozygous
form of sickle cell anemia, a severe disease
resulting from a single genetic mutation
occurring on the b-globin gene and re-
sponsible for the synthesis of abnormal
hemoglobin (Hb), known as HbS. HbS
has a propensity to polymerize under de-
oxygenated conditions, resulting in sickling
of red blood cells. Whereas patients with
sickle cell anemia are frequently exposed
to severe acute/chronic complications, SCT
carriers are usually asymptomatic because
the presence of normal Hb (HbA) in red
blood cells limits HbS polymerization (5).
However, very recent epidemiological data
on large U.S. cohorts demonstrated that
SCT increases the risks for venous throm-
boembolism (6,7), ischemic stroke (8), and
glomerulopathy (9) in Afro-American indi-
viduals. Althoughnever investigated, these
findingsmay suggest that vascular function
could be impaired in SCT (10). The high
prevalence of SCT in Sub-Saharan Africa
and the growing proportion of this popu-
lationwith T2DM imply that a highnumber
of individuals may have both conditions.
Although the association of T2DM and
SCT has been suspected to increase the
risks for vascular disorders (11), no study
has investigated vascular function in this
population. We hypothesized that SCT
could accentuate the vascular dysfunction
observed in T2DM.
The current study, conducted in Sene-
gal, compared for the first time the vas-
cular function, hemorheological profile,
and biomarkers of oxidative stress, in-
flammation, NOmetabolism, and vascular
adhesion process between healthy indi-
viduals, subjects with T2DM, SCT carriers,
and patients with both T2DM and SCT.
RESEARCH DESIGN AND METHODS
Participants
The current study was conducted at the
Cheikh Anta Diop University (UCAD).
The protocol was designed in accordance
with the Declaration of Helsinki and was
approved by the Ethics Committee of
Cheikh Anta Diop University (008/2013/
CER/UCAD). Participants were informed
of the procedures and purposes of the
study and gave written informed consent
to participate. Twenty-eight individuals
with T2DM were randomly selected at
the Anti-diabetes Centre (Marc Sanakalé)
at the Abass Ndao Hospital in Dakar: 14
without and 14 with SCT (groups with
T2DM and T2DM-SCT, respectively).
Thirty-two individuals without diabetes
or any other known diseases were re-
cruited in the general population of Dakar
and in blood donors from the National
Center of Blood Transfusion (CNTS) of
Dakar: 14 without SCT (CONT) and 18
individuals with SCT (SCT). The presence
or absence of SCT in each individual was
already known by the CNTS or the Anti-
diabetes Centre and was confirmed by
biological analysis (isoelectric focusing,
citrate agar electrophoresis, high-
performance liquid chromatography,
and a solubility test). Patients with leg
ulcers or cardiac disorders were ex-
cluded from the study. All participants
were Senegalese.
Blood Samples
All the subjects arrived at the Laboratory
ofMedical Physiology (Cheikh Anta Diop
University) at 8:00 A.M. in fasting condi-
tion. They were asked to refrain from
any physical activity for at least 24 h
before the experimental day. Blood
was drawn into fluoride tubes (5 mL)
for glucose measurement, heparin
tubes (5 mL) for lipid measurement, cit-
rate tubes (5 mL) for plasma fibrinogen
determination, and EDTA tubes (5 mL)
for the analyses of blood rheology, he-
moglobin A1c (HbA1c), oxidative stress,
and inflammatory and NO metabolism
biomarkers.
Routine Biochemical Parameters
Plasma lipids (triglycerides [TG] and total,
HDL, and LDL cholesterol), fibrinogen,
and glucose levels were evaluated using
standard enzymatic methods. HbA1c
was measured using high-performance
liquid chromatography (DiaStat; Bio-Rad,
Hercules, CA).
Hemorheological Parameters
Blood viscosity was measured with a
cone-plate viscometer (Pro DV-II+, with
CPE40 spindle; Brookfield, Middleboro,
MA) at varying shear rates (5.62, 11.25,
22.5, 45, 90, and 225 s21) and 378C, as
recommended (12). Plasma viscosity was
evaluated at 750 s21 and 378C. Hemato-
crit (Hct) was measured after blood mi-
crocentrifugation (1,500g, 5 min, 258C;
Jouan-Hema-C, Saint Herblain, France).
Markers of Oxidative Stress, NO
Metabolism, and Inflammation
Blood was rapidly centrifuged after sam-
pling and plasma was stored at 2808C
until analysis.
Advanced Oxidation Protein Products
Advanced oxidation protein products
(AOPPs) areplasma compounds preferen-
tially formed fromalbumin by chlorinated
oxidants produced by myeloperoxidase.
AOPPs stimulate both monocyte respira-
tory burst and TNF-a synthesis (13),
which participates in the pathophysiology
of several cardiovascular disorders asso-
ciated with phagocyte-derived oxidative
stress (14). AOPPs were determined in
plasma using a semiautomated method
(15) based on the absorption of AOPPs
at 340 nm and at low pH. AOPPs were
measured by spectrophotometry after
addition of acetic acid and were cali-
brated with a chloramine-T solution that
absorbs at 340 nm in the presence of po-
tassium iodide. The absorbance of the
plasma diluted in PBS (1:4, volume for
volume) mixed with acetic acid was im-
mediately read at 340 nm against a blank
containing PBS, potassium iodide, and
acetic acid.
Malondialdehyde
Concentrations of plasma malondial-
dehyde (MDA) were determined as
thiobarbituric-reactive substances (16).
The pink chromogen, resulting from the
fixation of thiobarbituric acid to MDA
at low pH and after 1 h at 1008C, was
extractedwithn-butanoland itsabsorbance




AGEs in plasmawere determined byELISA
according to the manufacturer’s instruc-
tions (Cell Biolabs, San Diego, CA).
Nitrotyrosine
Concentration of total (free + protein bound)
plasma nitrotyrosine, as an end product of
protein nitration by peroxynitrite (ONOO2),
was measured by a competitive ELISA test
using 96-well plates coated with nitrated
BSA at 5mg/mL in coating buffer (50mmol/L
NaHCO3), as previously described (17).
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Ferric-Reducing Antioxidant Power
Ferric-reducing antioxidant power (FRAP)
was measured according to previous
method (18) based on the ferric-reducing
ability of plasma. The absorbance of the
plasma in the presence of Fe3+ and tripyr-
idyltriazine was read after 4min at 593 nm
using an aqueous solution of known Fe2+
concentration (FeSO4, 7H2O2) as standard.
NO End Products
NOendproducts (NOx) (sumofnitrite and
nitrate) were measured in plasma using
the Griess method previously described
(19). Plasma was previously incubated
with nitrate (NO3
2) reductase and nico-
tinamide adenine dinucleotide phosphate
for 40 min to reduce NO3
2 in NO2
2.
Soluble Vascular Cell Adhesion Molecule-1
and Interleukin-1b
Soluble vascular cell adhesionmolecule-1
(sVCAM-1) and interleukin-1b (IL-1b)




The possible interference of color compo-
nents in plasma on the absorbance mea-
sured for AOPP, MDA, FRAP, and NOx
assays is a limitation of these techniques.
Flow-Mediated Dilation
Flow-mediated dilation (FMD) of the
brachial artery was measured by the
same experienced cardiologist and by
ultrasound according to the guidelines
described by Corretti et al. (20). Brachial
artery ultrasonography was performed
after resting in the supine position for
15 min and in the fasting state. All par-
ticipants refrained from drinking bever-
ages containing caffeine or alcohol for
12 h before the examination and were
also advised not to take antihyperten-
sive or vasodilator drugs the day of ex-
amination. Patients were examined in a
quiet and temperature-controlled room
(258C). The right arm was extended and
immobilized with an angle of;608 from
the trunk of the body. A 10-MHz linear
transducer connected to an ultrasound
device (Sonoline G50; Siemens) was
placed on the brachial artery at 1–2 cm
proximal to the elbow joint. After scan-
ning the baseline artery diameter, the
cuff was rapidly inflated to 50 mmHg
above systolic blood pressure and kept
for 5 min. By rapid deflation of the cuff,
reactive hyperemia was induced and
scanning was performed at 5, 30, 60,
90, and 120 s and 10 min after cuff de-
flation to obtain the FMD, expressed in
percentage of the baseline diameter
(%FMD). Because of limited technical
(software) resources, we were not able
to capture the diameter continuously.
FMD was measured in duplicate for
each patient with at least 1 h in resting
condition between the two measure-
ments, and the mean of the two FMD
values was calculated. A difference of
,10% between the two measurements
was considered as acceptable. The car-
diologist who performed FMD and pulse
wave velocity (PWV) experiments was
blinded to the diagnosis of the patient.
Blood Velocity, Shear Rate, and Shear
Stress
The blood velocity profile was obtained at
the same time as diameter determination
using a 7.5–10-MHz linear transducer B
mode operated in the high-pulsed repeti-
tion frequency mode (2–25 kHz) with a
sample volume of 1.5–3.5 cm in depth.
Care was taken to avoid bias by using
scale adjustments, especially after cuff
release. In duplex mode, real-time ultra-
sound imaging and PWV profile were
viewed simultaneously during the cardiac
cycle (systolic and diastolic), and shear
rate was calculated using the following
equation: 4 3 mean blood velocity (cm/s)/
diameter (cm) (21). Shear stress was the
product of blood viscosity by shear rate
(22). Most of the previous studies in the
field of cardiovascular physiology used a
single and/or unmeasured blood viscosity
(i.e., estimated from Hct level) value to
calculate shear stress, which introduced
biased values. Blood is a shear-thinning
fluid, with its viscosity value being affected
by the shear rate (23). Indeed, we used
the blood viscosity values obtained with
the cone plate viscometer to calculate the
individualized shear stress for every partic-
ipant. Blood viscosity level was chosen at
the viscometer’s shear rate, corresponding
to the in vivo shear rate calculated from
blood velocity and diameter.
Systolic and Diastolic Arterial Pressure
and PWV
Systolic and diastolic blood pressures
were manually measured three times in
the left arm using a manual sphygmoma-
nometer (Omron M3; Intellisense, Kyoto,
Japan) in standardized sitting position
and after 30 min of rest (24). The carotid-
femoral PWV was measured with an
automated system (Pulse Pen; DiaTecne,
Milan, Italy). The carotid and femoral
waveformswere acquired simultaneously
with two pressure-sensitive transducers,
and the transit time of the pulse was cal-
culated by the system software. The dis-
tance between the two arterial sites was
measured on the body using a tape mea-
sure, and the PWVs were calculated as
the distance divided by time (m/s). At
least 12 successive readings were used
for analysis to cover a complete respira-
tory cycle. All PWV measurements were
performed by the same operator, and the
mean of three consecutive measures
(each taken 5 min apart) was calculated.
Associated Complications
Three complications were investigated:
retinopathy by indirect ophthalmoscopy
with a noncontact slip lamp lens (25),
hypertension using the American Heart
Association recommendation (24), and
albuminuria by using the Hemocue 20
system (Angelholm, Sweden) (26).
Statistical Analysis
Results are expressed as mean6 SD. An-
thropometric, biochemical, hemody-
namic, and hemorheological parameters;
oxidative stress biomarkers; and adhesion
molecules were compared between the
four groups using a one-way ANOVA
with Holm-Bonferroni correction. x2 or
Fischer exact test was used to compare
the frequency of retinopathy, hyperten-
sion, and glomerulopathy between the
groups. Pearson correlation was used to
test the associations between FMD and
several biomarkers by pooling the
groups. Multivariate linear regression
model was used to predict the indepen-
dent associations between different
variables of interest with vascular dys-
function. The significance level was de-
fined as P , 0.05. Analyses were
conducted using SPSS software (version





None of the participants included in this
study had a previous history of smoking.
The percentage of patients under met-
formin (Glucophage) treatment was not
significantly different between the
groups with T2DM-SCT (36%) and
T2DM (50%). Two patients of the group
with T2DM-SCT were treated with
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calcium channel blocker (Amlor) and one
of the group with T2DM with ACE inhibi-
tor (Tritazide). Sex distribution was not
significantly different between the four
groups. The duration of diabetes was
not significantly different between the
groups with T2DM-SCT (2.9 6 1.7 years)
and T2DM (3.06 1.9 years).
BMI was greater in patients with T2DM
compared with subjects without diabetes
independently of SCT (Table 1). The group
with T2DM was older than the three
other groups (Table 1). Whereas no
significant difference in diastolic blood
pressure was found between the four
groups after Holm-Bonferroni correction,
we found significant differences regard-
ing systolic blood pressure: higher in pa-
tients with T2DM-SCT and patients with
T2DM compared with individuals with
SCT and higher in the group with T2DM
than in CONT subjects (Table 1). Fasting
glucose andHbA1c levelswere higher, and
HDL concentration was lower, in patients
with diabetes independently of SCT, com-
pared with the subjects without diabetes.
Fibrinogenwas greater in individuals with
T2DM-SCT compared with the CONT
group and group with T2DM. TG level
was not different between the four
groups.Ahigher frequencyofparticipants
with both T2DM and SCT had arterial
hypertension (64.3 vs. 14.3, 16.7, and
50.0% in the CONT group, group with
SCT, and group with T2DM, respectively;
P, 0.01) ormicroalbuminuria (57.1 vs. 0,
0, and 28.6% in the CONT group, group
with SCT, and group with T2DM, respec-
tively; P, 0.001). Retinopathy was more
frequent in the two groups with diabetes
(42.9 and 50% in the groups with T2DM
and T2DM-SCT, respectively) compared
with the two groups without diabetes
(0 and 5.6% in the CONT group and group
with SCT, respectively; P , 0.01).
Hemorheological Parameters
Hct was not different between the four
groups (Table 2). Blood viscosity was
higher in the groups with T2DM-SCT,
T2DM, and SCT compared with the
CONT group at all shear rates. The
two groups with diabetes also had
higher blood viscosity than the group
with SCT in the 5.52–45 s21 shear rate
range. At 90 s21, blood viscosity tended
to be higher in patients with T2DM-SCT
compared with patients with T2DM
(P = 0.066) and individuals with SCT
(P = 0.064). At 225 s21, blood viscosity
was significantly different between the
groups with T2DM-SCT and T2DM. Plasma
viscosity of patients with diabetes (with or
without SCT) was higher than in subjects
without diabetes in the two other groups.
Markers of Oxidative Stress,
Inflammation, and NO Metabolism
Parameters
The two groups with diabetes had
higher AGEs and IL-1b levels than indi-
viduals with SCT and CONT individuals
but, most importantly, AGEs and IL-1b
concentrations were higher in the group
with T2DM-SCT than in patients with
T2DM (Table 3). AOPP was greater in
the group with T2DM-SCT and tended to
be higher in individuals with SCT
(P = 0.072) compared with the CONT
group. Nitrotyrosine level was greater in
patientswith diabetes and SCT than in the
group with SCT and the CONT group.
T2DM-SCT was the only group expressing
higher MDA concentrations compared
with the CONT group. No significant dif-
ference was observed for FRAP, VCAM-1,
and NOx between the four groups.
Baseline Hemodynamic Parameters,
FMD, and PWV
Diastolic and systolic diameters were
not different between the four groups
(Table 2). Whereas systolic blood flow
did not differ between the four groups,
diastolic blood flow was increased in the
groups with T2DM-SCT and T2DM com-
pared with the two other groups. Systolic
shear rate was not different between the
four groups, whereas diastolic shear rate
was higher in the two groups with diabe-
tes comparedwith theCONTgroup (Table
2). Diastolic shear rate was also higher in
T2DM-SCT than in individuals with SCT.
Systolic shear stress of patients with
T2DM-SCT was increased in comparison
with CONT. Diastolic shear stress was in-
creased in the two groups with T2DM
compared with CONT individuals. More-
over, the group with T2DM-SCT ex-
pressed higher diastolic shear stress
than the group with SCT. Despite these
differences in shear rates and shear
stresses, baseline arterial diameter was
not different between the four groups.
Figure 1 shows the kinetics of FMD after
cuff deflation in the four groups. Signifi-
cant differences were observed at 60, 90,
and 120 s. When looking at the details for
the FMD determined at 90 s after cuff de-
flation (Fig. 2A), patients with T2DM-SCT
expressed lower FMD than the three other
groups. We also noted a reduced FMD in
patients with T2DM compared with the
CONT group and a trend for SCT carriers
to have lower FMD than healthy controls
(P = 0.066). ANCOVA with age, sex, BMI,
and arterial pressures as covariates also
demonstrated lower FMD in the patients
with T2DM-SCT (P,0.01) comparedwith
the other groups. FMD measured 90 s
after cuff deflation correlated with AGEs
(P , 0.05; r = 20.28), MDA (P , 0.05;
r=20.36), sVCAM-1 (P,0.05; r=20.30),
Table 1—Characteristics and biochemical parameters of patients with diabetes
with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT)
or without (CONT) SCT
T2DM-SCT T2DM SCT CONT
Sex (male/female) 7/7 7/7 8/10 8/6
Age (years) 42.4 6 9.3 52.8 6 11.6***,†,‡ 42.8 6 8.2 40.4 6 5.7
BMI (kg/m2) 29.5 6 4.7**,††† 27.0 6 4.6*,† 23.6 6 3.6 24.4 6 2.8
Diastolic BP (mmHg) 84 6 10 86 6 10 72 6 10 77 6 10
Systolic BP (mmHg) 128 6 17† 131 6 16*,††† 118 6 14 119 6 13
HbS (%) 36.0 6 2.0 d 38.9 6 2.7 d
Glucose (g/L) 1.7 6 0.6***,††† 1.8 6 0.6***,††† 1.0 6 0.1 0.9 6 0.1
HbA1c (%) 7.5 6 3.0**,†† 7.3 6 2.0*,†† 4.8 6 1.2 5.0 6 1.2
(mmol/mol) 58 6 9**,†† 56 6 0*,†† 29 6 0 31 6 0
LDL (g/L) 1.1 6 0.4† 1.0 6 0.3 0.7 6 0.4 0.7 6 0.3
HDL (g/L) 0.5 6 0.2***,†† 0.6 6 0.3**,† 0.8 6 0.2 0.9 6 0.2
TG (g/L) 1.5 6 0.6 1.2 6 0.7 1.2 6 0.3 1.3 6 0.4
T-Chol (g/L) 1.8 6 0.4 1.7 6 0.3 1.5 6 0.5 1.4 6 0.4
Fibrinogen (g/L) 5.3 6 1.7*,# 3.9 6 1.9 4.0 6 1.0 3.4 6 1.0
Data are means6 SD. BP, blood pressure; T-Chol, total cholesterol. *Different from CONT, P,
0.05. **P , 0.01. ***P , 0.001. †Different from SCT, P , 0.05. ††P , 0.01. †††P , 0.001.
#Different from T2DM, P , 0.05. ‡Different from T2DM-SCT, P , 0.05.
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IL-1b (P, 0.05; r =20.37), and NOx (P,
0.05; r = 0.28). Unfortunately, it was not
possible to normalize FMD values by
nitroglycerin-mediated dilation, which
represents the maximal dilation that can
be achieved. We were able to correct the
FMD values at 90 s after cuff deflation by
the shear stress measured at that time
(corrected FMD). We still observed lower
corrected FMD in the group with T2DM-
SCT compared with subjects with T2DM,
subjects with SCT, and CONT subjects (Fig.
2B). The group with T2DM and the group
with SCT had lower corrected FMD than
the CONT group, and SCT carriers and pa-
tients with T2DM were significantly
different. Mean FMD was decreased in
individuals with T2DM-SCT compared
with the CONT group (Fig. 2C). Corrected
FMD measured at 90 s correlated with
FRAP (P , 0.05; r = 0.35), AGEs (P ,
0.001; r = 20.42), nitrotyrosine (P ,
0.05; r = 20.32), MDA (P , 0.05; r =
20.33), sVCAM-1 (P , 0.05; r = 20.26),
IL-1b (P , 0.001; r = 20.52), and AOPP
(P , 0.05; r = 20.25). Carotid-femoral
PWV was increased in the group with
T2DM-SCT compared with the three
other groups and in patients with T2DM
compared with the CONT group (Fig. 2D).
PWV correlated with AOPP (P , 0.05;
r = 0.32), IL-1b (P , 0.01; r = 0.38), and
AGEs (P , 0.01; r = 0.42).
Multivariate Analyses
Because of the limited sample size (n =
60), only seven variables were included
in the model to predict FMD measured
at 90 s: sex, BMI, age, LDL, nitrotyro-
sine, AGEs, and IL-1b levels. Systolic
and diastolic blood pressures, as well
as lipids markers (except for LDL), were
not included in the model because
of the high risk of colinearity effect
(variance inflation factor .3). The
other lipid characteristics were not in-
cluded in the model because of the
high risk of colinearity with BMI. The
overall model was statistically signifi-
cant (R2 = 0.23; df = 7; P , 0.05), and
IL-1b was the only factor indepen-
dently associated with FMD (b =
20.35; P = 0.034). When replacing
FMDwith the corrected FMD, the over-
all model was still significant (R2 =
0.38; df = 7; P , 0.01) and IL-1b re-
mained the only factor independently
Table 2—Hemorheological and hemodynamic parameters of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT
and of healthy individuals with (SCT) or without (CONT) SCT
T2DM-SCT T2DM SCT CONT
Hct (%) 40.6 6 2.3 41.3 6 2.1 41.8 6 2.2 40.5 6 1.3
Blood viscosity (cP)
5.62 s21 11.1 6 1.0***,† 10.9 6 0.8***,† 10.2 6 0.8** 9.2 6 0.9
11.25 s21 9.7 6 1.0***,† 9.8 6 0.8***,†† 8.9 6 0.6* 8.2 6 0.8
22.5 s21 8.7 6 0.9***,†† 8.7 6 0.6***,††† 7.9 6 0.5* 7.2 6 0.6
45 s21 7.7 6 0.8***,† 7.6 6 0.5***,† 7.1 6 0.5* 6.4 6 0.3
90 s21 7.0 6 0.7*** 6.5 6 0.4* 6.5 6 0.5*** 5.8 6 0.4
225 s21 6.3 6 0.7***,# 5.8 6 0.4*** 5.9 6 0.4*** 4.9 6 0.4
Plasma viscosity (cP) 1.8 6 0.4**,†† 1.8 6 0.4**,†† 1.3 6 0.3 1.4 6 0.3
Baseline diameter (mm)
Systolic 4.0 6 0.5 4.0 6 0.5 4.0 6 0.4 4.2 6 0.5
Diastolic 3.7 6 0.4 3.8 6 0.5 3.8 6 0.4 3.9 6 0.5
Baseline blood flow (mL/min)
Systolic 331 6 112 310 6 120 299 6 98 292 6 88
Diastolic 286 6 106**,†† 266 6 84*,† 202 6 40 197 6 53
Baseline shear rate (s21)
Systolic 504.5 6 135.5 452.0 6 117.0 445.0 6 120.1 386.0 6 99.8
Diastolic 156.8 6 63.3***,† 142.1 6 47.8* 110.3 6 31.2 95.7 6 25.4
Baseline shear stress (dyn/cm2)
Systolic 26.7 6 9.5*** 22.3 6 6.4 23.2 6 7.1 16.6 6 3.9
Diastolic 10.5 6 4.5***,†† 8.9 6 2.8* 7.1 6 2.0 5.6 6 1.6
Data are means 6 SD. *Different from CONT, P , 0.05. **P , 0.01. ***P , 0.001. †Different from SCT, P , 0.05. ††P , 0.01. †††P , 0.001.
#Different from T2DM, P , 0.05.
Table 3—Markers of oxidative stress, inflammation, and NO metabolites of patients with diabetes with (T2DM-SCT) or without
(T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT
T2DM-SCT T2DM SCT CONT
AOPP (mmol/L) 122.9 6 47.1** 88.1 6 32.6 93.6 6 66.0 63.1 6 20.3
MDA (mmol/L) 37.3 6 16.7* 30.3 6 16.0 26.8 6 7.1 22.9 6 11.5
Nitrotyrosine (mmol/L) 1.8 6 1.2***,† 1.1 6 0.6 0.8 6 0.5 0.6 6 0.5
AGEs (mg/mL) 2.7 6 1.0***,†††,### 1.5 6 0.9*,† 0.7 6 0.8 0.5 6 0.4
FRAP (mmol/L 449.2 6 144.4 555.3 6 127.6 568.5 6 243.3 627.5 6 269.0
sVCAM-1 (ng/mL) 1,079.4 6 657.2 826.2 6 179.1 897.1 6 309.3 724.0 6 178.8
IL-1b (ng/mL) 7.2 6 3.0***,†††,### 3.8 6 2.1*,† 1.9 6 1.0 1.7 6 0.9
NOx (mmol/L) 17.8 6 5.9 21.2 6 11.0 23.4 6 9.5 21.9 6 4.4
Data are means6 SD. *Different from CONT, P, 0.05. **P, 0.01. ***P, 0.001. †Different from SCT, P, 0.05. †††P, 0.001. ###Different from
T2DM, P , 0.001.
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associated with corrected FMD (b =
20.32; P = 0.047). When replacing
FMD with the PWV, the model was also
significant (R2 = 0.31; df = 7; P , 0.05)
and AGEs was independently associated
with PWV (b = 0.40, P = 0.018). Replace-
ment of nitrotyrosine with AOPP in the
models did not affect the results.
CONCLUSIONS
Our study is the first to suggest that SCT
could worsen the vascular dysfunction
among patients with T2DM. In addition,
we found elevated blood viscosity and
oxidative stress in patients with T2DM-
SCT, which, in association with the vas-
cular dysfunction, could increase the risk
for vascular disorders in this population.
The principal aim of this study was to
test whether the presence of SCT could
worsen the vascular dysfunction and the
biological abnormalities observed in
patients with T2DM. Despite the fact
that individuals with T2DM were older
than subjects with T2DM-SCT, their vas-
cular function was less altered. PWV,
FMD, and corrected FMD were blunted
in subjects with T2DM-SCT compared
with the three other groups, demon-
strating increased arterial stiffness
and a loss of vascular reactivity in these
subjects, which, in other diseases, have
been shown to increase the risks for
Figure 1—Kinetics (log scale) of mean FMD after cuff deflation in patients with diabetes with
(T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT.
SD values are not shown to avoid a cluttered figure. Significant differences between groups:
*P , 0.05; ***P , 0.001.
Figure 2—FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without
(CONT) SCT. FMDmeasured at 90 s (A), FMDmeasured at 90 s corrected by shear stress values (B), mean FMD determined over 10 min after cuff
deflation (C ), and PWV (D) in the different groups. The two extremities of the horizontal bars indicate the difference between two given groups
(*P , 0.05; ***P , 0.001). Means 6 SD.
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cardiovascular morbidity and/or mortal-
ity (27,28). In agreement with this
assumption, a higher number of partic-
ipants with both T2DM and SCT had
arterial hypertension ormicroalbuminuria
compared with the three other groups.
However, these findings need to be con-
firmed in larger cohorts. Moreover, we do
not know how many females of the cur-
rent study have achieved menopause,
nor the effect of menopause on vascular
function and cardiovascular morbidities in
females with both T2DM and SCT.
Although the degree of metabolic ab-
normalities (i.e., lipids and glucose
levels) was similar in the groups with
T2DM and T2DM-SCT, the levels of
plasma AOPP and MDA were increased
in T2DM-SCT, suggesting enhanced
ROS production in this population. We
suspect that the slightly increased
oxidative stress related to SCT, which
has previously been reported in this
population (29), could have promoted
the greater AGE formation and nitroty-
rosine observed in the group with
T2DM-SCT (30). The inducible NO syn-
thase (iNOS) activity is usually upregu-
lated in the context of inflammation
(31), which would result in higher NOx
levels. However, the enhanced oxidative
stress found in the groupwith T2DM-SCT
could have led to the rapid formation of
peroxynitrite (ONOO2) (32), which could
also explain the absence of difference in
plasma NOx levels between the groups.
The ligation of AGE to its receptor
(RAGE) on endothelial cells may pro-
mote oxidative stress, inflammation,
and endothelial activation (33). The neg-
ative correlations found between FMD,
corrected FMD, or PWV and the differ-
ent markers of oxidative stress and
inflammation suggest a role of these
biological abnormalities in the impair-
ment of vascular function. The patholog-
ical role of oxidative stress in vascular
dysfunction in diabetes is well known.
Acute vitamin C infusion has been shown
to improve FMD (34) and to limit the
FMD impairment in response to hyper-
glycemia in patients with diabetes (35).
Further experiments are needed to
directly demonstrate the role of oxida-
tive stress in vascular dysfunction in sub-
jects with T2DM-SCT.
Multivariate analyses suggest that in-
flammation and AGE could be the most
important factors playing a role in the vas-
cular dysfunction and arterial remodeling,
respectively, since IL-1b and AGE were in-
dependently associated with the FMD
and PWV values, respectively. Growing
evidence in the literature suggests a key
role of inflammation in triggering vascular
dysfunction in various diseases (36,37).
For instance, mild to moderate inflamma-
tionmay decrease the transcription of the
endothelial NOS, which would result in
lower NOx levels. At the same time, in-
flammation may upregulate iNOS. How-
ever, inflammation also promotes the
production of ROS, which, by reacting
with NO, would lead to the formation of
peroxynitrite. In addition, this accumula-
tion of free radicals may catalyze the
transformation of arachidonic acid to
F2-isoprostances, such as 8-epi PDF2a, a
potent vasoconstrictor. Finally, inflamma-
tion may stimulate the production of
cyclo-oxygenase–derived prostanoids,
which would cause vasoconstriction.
Although the cause-effect relationship be-
tween enhanced inflammation and vascu-
lar dysfunction in patients with T2DM-SCT
is not established in our study, one may
suspect that anti-inflammatory medica-
tion could be beneficial in this population.
Further studies are needed to test this
hypothesis.
Blood viscosity measured at high shear
rate (i.e., at 225 s21) was higher in pa-
tients with T2DM-SCT than in patients
with T2DM. Because plasma viscosity
andHctwere not different between these
two groups, one may suggest that the
greater blood viscosity found in the for-
mer group was related to a reduction in
red blood cell deformability (23,38,39).
Both reduced red blood cell deformability
and increasedblood viscosity increase the
risk formicro- andmacrovascular compli-
cations (23). Indeed, as patients with
T2DM-SCT display higher blood viscosity
and fibrinogen than patients with only
T2DM, they could be at higher risk for
developing cardiovascular complications
than the other groups, including patients
with T2DM.
Our study suggests that SCT exacer-
bates inflammation and oxidative stress
in patients with T2DM, leading to further
impairment of vascular function and
blood rheology, which could in turn in-
crease the risk for developing micro- and
macrovascular disorders. Although larger
cohort studies are needed to explore
the link between these diseases/genetic
conditions and the development of sev-
eral cardiovascular complications, we
suggest that patients with both T2DM
and SCT should be more frequently mon-
itored for cardiovascular health status.
Further studies are also needed to test
the effects of oxidative stress inhibition/
modulation on the vascular function of in-
dividuals with T2DM-SCT. Based on the
predictions of T2DM prevalence within
the next 10 years in African regions where
the occurrence of SCT can be 10–15% or
greater, this detrimental association could
become a worldwide health issue.
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